Employees: 260
Size Kura Oncology (KURA) is a United States Health Care company (Biotechnology) with a market value of $674M, the 2486th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.34 on 18 Nov 2026.
Performance Over six months the shares fell 29.0%, against -13.8% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth Revenue fell 23.8% over the last twelve months (peer median +18.4%); the operating margin is -394.3% (peer median -37.8%).
Valuation It trades at 2.6× enterprise value to sales against a peer median of 8.8× (3rd cheapest of 15).
Short interest Short interest is 14.2% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $79.3M | $67.5M | $53.9M | $0 | $0 |
| Revenue growth | — | +25% | — | — | — |
| Gross profit | $77.3M | $66.4M | $53.0M | -$849,000 | -$759,000 |
| EBITDA | -$311M | -$303M | -$192M | -$165M | -$139M |
| Net income | -$293M | -$279M | -$174M | -$153M | -$136M |
| Free cash flow | -$89.1M | -$70.7M | $134M | -$125M | -$111M |
| Capital expenditure | $3.55M | $6.64M | $472,000 | $168,000 | $626,000 |
| Total debt | $25.8M | $20.5M | $16.6M | $17.2M | $14.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | KURA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.4% | -7.0% | 2nd lowest of 21 |
| 6-month return | -29.0% | -13.8% | 4th lowest of 19 |
| Distance from 52-week high | -47.2% | -44.5% | 9th lowest of 21 |
| Revenue growth (TTM) | -23.8% | +18.4% | 2nd lowest of 15 |
| Operating margin | -394.3% | -37.8% | 5th lowest of 16 |
| EV / Sales | 2.6× | 8.8× | 3rd cheapest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |